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Visceral adiposity in obesity causes excessive 
free fatty acid (FFA) flux into the liver via the 
portal vein and may cause fatty liver disease and 
hepatic insulin resistance. However, because 
animal models of insulin resistance induced by 
lipid infusion or a high-fat diet are complex and 
may be accompanied by alterations not restricted 
to the liver, it is difficult to determine the 
contribution of FFAs to hepatic insulin resistance. 
Therefore, we treated H4IIEC3 cells, a rat 
hepatocyte cell line, with a monounsaturated 
fatty acid (oleate) and a saturated fatty acid 
(palmitate) to investigate the direct and initial 
effects of FFAs on hepatocytes. We show that 
palmitate, but not oleate, inhibited 
insulin-stimulated tyrosine phosphorylation of 
insulin receptor substrate 2 and serine 
phosphorylation of Akt, through c-Jun 
NH2-terminal kinase (JNK) activation. Among 
the well-established stimuli for JNK activation, 
reactive oxygen species (ROS) played a causal 
role in palmitate-induced JNK activation. In 
addition, etomoxir, an inhibitor of carnitine 
palmitoyltransferase-1, which is the rate-limiting 
enzyme in mitochondrial fatty acid β-oxidation, 
as well as inhibitors of the mitochondrial 
respiratory chain complex 
(thenoyltrifluoroacetone and carbonyl cyanide 
m-chlorophenylhydrazone) decreased 
palmitate-induced ROS production. Together, 
our findings in hepatocytes indicate that 
palmitate inhibited insulin signal transduction 
through JNK activation and that accelerated 
β-oxidation of palmitate caused excess electron 
flux in the mitochondrial respiratory chain, 
resulting in increased ROS generation. Thus, 
mitochondria-derived ROS induced by palmitate 
may be major contributors to JNK activation and 
cellular insulin resistance. 
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INTRODUCTION 
Insulin is the major hormone that inhibits 
gluconeogenesis in the liver. Visceral adiposity in 
obesity causes hepatic steatosis and insulin 
resistance. In an insulin-resistant state, impaired 
insulin action allows enhancement of glucose 
production in the liver, resulting in systemic 
hyperglycemia (1) and contributing to the 
development of type 2 diabetes. In addition, we 
have demonstrated experimentally that insulin 
resistance accelerated the pathology of 
steatohepatitis in genetically obese diabetic 
OLETF rats (2). In contrast, lipid-induced 
oxidative stress caused steatohepatitis and 
hepatic insulin resistance in mice (3). In fact, 
steatosis of the liver is an independent predictor 
of insulin resistance in patients with nonalcoholic 
fatty liver disease (4). 
It remains unclear whether hepatic steatosis 
causally contributes to insulin resistance or 
whether it is merely a resulting pathology. 
Excessive dietary free fatty acid (FFA) flux into 
the liver via the portal vein may cause fatty liver 
disease and hepatic insulin resistance. Indeed, 
elevated plasma FFA concentrations correlate 
with obesity and decreased target tissue insulin 
sensitivity (5). 
Experimentally, lipid infusion or a high-fat 
diet that increases circulating FFA levels 
promotes insulin resistance in the liver. 
Candidate events linking FFA to insulin 
resistance in vivo are the up-regulation of 
SREBP-1c (6), inflammation caused by 
activation of c-Jun amino-terminal kinase (JNK) 
(7) or IKKβ (8), endoplasmic reticulum (ER) 
stress (9), ceramide (10,11), and TRB3 (12). 
However, which event is the direct and 
initial target of FFA in the liver is unclear. Insulin 
resistance induced by lipid infusion or a high-fat 
diet is complex and may be accompanied by 
alterations not restricted to the liver, making it 
difficult to determine the contribution of FFAs to 
hepatic insulin resistance. For example, 
hyperinsulinemia and hyperglycemia secondary 
to the initial event also may contribute to the 
development of diet-induced insulin resistance in 
vivo (6). 
To address the early event(s) triggering the 
development of high-fat diet- or obesity-induced 
insulin resistance, we investigated the molecular 
mechanism(s) underlying the direct action of 
FFA on hepatocytes to cause insulin resistance in 
vitro, using the rat hepatocyte cell line H4IIEC3. 
We found that mitochondria-derived reactive 
oxygen species (ROS) were a cause of 






Materials—The antibody against IRS-2 was 
purchased from Upstate Biotechnology (Lake 
Placid, NY). Antibodies against 
phospho-tyrosine, Akt, phospho-Akt (Ser473), 
SAPK/JNK, phospho-SAPK/JNK 
(Thr183/Tyr185), and phospho-GSK-3 (Ser21/9) 
were purchased from Cell Signaling Technology 
(Beverly, MA). Antibodies against GSK-3 and 
phospho-c-Jun were from Santa Cruz 
Biotechnology (Santa Cruz, CA). Insulin from 
porcine pancreas, sodium palmitate, sodium 
oleate, myriocin, N-acetyl-L-cysteine, rotenone, 
TTFA, CCCP, oxypurinol, etomoxir, and 
tunicamycin were obtained from Sigma (St. 
Louis, MO). SP600125 and apocynin were from 
Calbiochem (La Jolla, CA). DL-a-tocopherol and 
H2DCFDA were from Wako (Osaka, Japan). 
Cell Culture and Fatty Acid Treatment—Studies 
were performed in the rat hepatoma cell line 
H4IIEC3, purchased from the American Type 
Culture Collection (Manassas, VA). Cells were 
cultured in DMEM (Invitrogen, Carlsbad, CA) 
supplemented with 10% FBS (Invitrogen), 
penicillin (100 U/mL), and streptomycin 
(0.1 mg/mL; Invitrogen). The cells were cultured 
at 37°C in a humidified atmosphere containing 
5% CO2, with medium changes three times a 
week. All studies were conducted using 80-90% 
confluent cells, which were treated with the 
indicated concentrations of FFAs in the presence 
of 2% FFA-free bovine serum albumin (FFA-free 
BSA, Sigma). 
Cell Harvest and Western Blot 
Analysis—H4IIEC3 hepatocytes, grown to 
80-90% confluency in six-well plates, were 
treated with the indicated reagents for 16 h in 
DMEM. After treatment, the cells were 
stimulated with insulin (1 ng/mL) for 15 min. 
Then, the cells were washed with ice-cold 
phosphate-buffered saline and lysed in buffer 
containing 20 mM Tris-HCl (pH 7.5), 5 mM 
EDTA, 1% NP-40, 2 mM Na VO3 4, 100 mM NaF, 
and a protease inhibitor cocktail (Sigma). After 
sonication with a Bioruptor (Cosmo Bio, Tokyo, 
Japan), the lysates were centrifuged to remove 
insoluble materials. The supernatants 
(10 µg/lane) were separated by SDS-PAGE and 
transferred onto polyvinylidene difluoride 
membranes (Millipore, Billerica, MA). For 
detection of phospho-tyrosine insulin receptor 
and phospho-tyrosine IRS-2, the supernatants 
(400 µg of protein) were immunoprecipitated 
with a phospho-tyrosine antibody and protein G 
beads for 2 h at 4°C before SDS-PAGE. The 
membranes were blocked in a buffer containing 
5% nonfat milk, 50 mM Tris (pH 7.6), 150 mM 
NaCl, and 0.1% Tween 20 (TBS-T) for 1 h at 
room temperature. They were then incubated 
with specific primary antibodies and 
subsequently with horseradish peroxidase-linked 
secondary antibodies. Signals were detected with 
a chemiluminescence detection system (ECL 
Plus Western blotting detection reagents; GE 
Healthcare Bio-Sciences, Piscataway, NJ). 
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Densitometric analysis was conducted directly 
on the blotted membrane, using a CCD camera 
system (LAS-3000 mini, Fuji-film, Tokyo, 
Japan) and Scion Image software. 
Quantitative Real-time PCR—Total RNA was 
extracted from cultured H4IIEC3 hepatocytes 
using an RNeasy mini kit (Qiagen, Germantown, 
MD), according to the manufacturer’s protocol. 
The cDNA was synthesized from total RNA 
(100 ng) using random hexamer primers, (N)6, 
and a High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Foster 
City, CA). Quantitative real-time PCR was 
performed with an ABI Prism 7900HT (Applied 
Biosystems). The set of specific primers and 
TaqMan probes in the present study were 
obtained from Applied Biosystems. The PCR 
conditions were one cycle at 50°C for 2 min and 
95°C for 10 min, followed by 40 cycles at 95°C 
for 15 s and 60°C for 1 min. 
Analysis of X-box binding protein-1 (XBP-1) 
mRNA Splicing—Total RNA was extracted from 
H4IIEC3 hepatocytes, and cDNA was 
synthesized as described above. The cDNA was 
amplified with a pair of primers (reverse 5′ CCA 
TGG GAA GAT GTT CTG GG 3′ and forward 5′ 
ACA CGC TTG GGG ATG AAT GC 3′) 
corresponding to the rat XBP-1 cDNA. The PCR 
conditions were initial denaturation at 94°C for 3 
min, followed by 30 cycles of amplification 
(94°C for 30 s, 58°C for 30 s, 72°C for 30 s) and a 
final extension at 72°C for 3 min. The PCR 
products were separated by 2.5% agarose gel 
electrophoresis. 
Measurement of Intracellular ROS—The 
intracellular formation of ROS was detected 
using the fluorescent probe 
2′,7′-dichloro-fluorescin diacetate (H2DCFDA), 
according to a published method (13). Briefly, 
H4IIEC3 hepatocytes, grown to 70–80% 
confluency in 96-well plates, were treated with 
the indicated reagents in DMEM for 8 h. After 
treatment, the cells were washed with 
phosphate-buffered saline, loaded with 10 µM 
H2DCFDA, and incubated for 30 min at 37°C. 
The fluorescence was analyzed using a plate 
reader (Fluoroskan Ascent FL, ThermoLab 
Systems, Franklin, MA). 
Measurement of Protein Carbonyls—The cellular 
concentration of proteins containing carbonyl 
groups (those which react with 
2,4-dinitrophenylhydrazine to form the 
corresponding hydrazone) was determined 
spectrophotometrically using a protein carbonyl 
assay kit (Cayman Chemical, Ann Arbor, MI) 
according to the manufacturer’s instructions and 
as described previously (14). 
Statistical Analysis—All values are given as 
means ± S.E. Differences between two groups 
were assessed using unpaired, two-tailed t-tests. 
Data involving more than two groups were 
assessed by one-way analysis of variance 
(ANOVA). All calculations were performed with 






Palmitate Inhibited Insulin Receptor-Mediated 
Signaling—Two long-chain fatty acids were 
chosen for the study: palmitate, a C16:0 saturated 
fatty acid, and oleate, a C18:1 monounsaturated 
fatty acid. To examine whether FFAs impaired 
insulin signal transduction in H4IIEC3 
hepatocytes, we assessed the effect of FFAs on 
insulin-stimulated tyrosine phosphorylation of 
IRS-2 and serine phosphorylation of Akt and 
GSK-3α (Fig. 1). Incubation with 0.25 mM 
palmitate inhibited insulin-stimulated tyrosine 
phosphorylation of IRS-2 by 40% in H4IIEC3 
cells. Downstream of IRS-2, insulin-stimulated 
serine phosphorylation of Akt and GSK-3α were 
also inhibited by 0.25 mM palmitate treatment, 
by 80% and 70%, respectively, indicating an 
insulin-resistant state. However, the protein 
levels of total IRS-2, Akt, and GSK-3 were 
unaffected by palmitate. Furthermore, we 
confirmed that palmitate, but not oleate, impaired 
insulin-stimulated Akt serine phosphorylation in 
the human hepatoma cell line HepG2 
(Supplemental Fig. 1).  
JNK Activation by Palmitate Contributed to 
Palmitate-Induced Insulin Resistance—JNK, a 
stress-activated protein kinase, has been reported 
to phosphorylate IRS-1 and -2 at serine residues 
(15,16). Serine phosphorylation of IRSs impairs 
IRS tyrosine phosphorylation, leading to a 
reduction in insulin receptor-mediated signaling. 
Many studies have verified the role of JNK in 
fat-induced insulin resistance in several 
experimental systems (7,17,18). Thus, we next 
examined the effect of FFAs on JNK activation 
and its involvement in insulin signaling. 
Palmitate, but not oleate, dramatically increased 
phosphorylated JNK and c-Jun (Fig. 2). A potent 
and selective inhibitor of JNK, SP600125 (19), 
reversed the palmitate-induced phosphorylation 
of c-Jun (Fig. 2), suggesting that palmitate 
activated JNK. To test whether 
palmitate-induced JNK activation mediated 
cellular insulin resistance, we inhibited the JNK 
pathway with SP600125. SP600125 
dose-dependently improved insulin-stimulated 
serine phosphorylation of Akt and GSK-3 in 
H4IIEC3 hepatocytes exposed to palmitate (Fig. 
3). These results suggest that JNK activation by 
palmitate contributed to palmitate-induced 
insulin resistance. 
Pathways for SREBP-1c and ER Stress were not 
Involved in Palmitate-Induced JNK Activation 
and Insulin Resistance in H4IIEC3 
Hepatocytes—The SREBP-1c pathway has been 
reported to play a role in diet-induced insulin 
resistance in vivo. Ide et al. (6) found that 
high-sucrose diet-induced hyperglycemia and 
hyperinsulinemia up-regulated hepatic 
expression of SREBP-1c, leading to 
down-regulation of IRS-2 at the transcriptional 
level. However, in the present study, palmitate 
dramatically down-regulated the expression of 
SREBP-1c in H4IIEC3 hepatocytes 
(Supplemental Fig. 2). Consistent with this, the 
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mRNA (Supplemental Fig. 2) and protein (Fig. 1) 
levels of IRS-2 were unaffected by palmitate. 
Thus, palmitate itself did not appear to cause 
insulin resistance in hepatocytes via the 
SREBP-1c pathway. 
ER stress is induced in insulin-resistant 
states such as obesity and type 2 diabetes, and in 
turn, this stress has been shown to lead to the 
inhibition of insulin signaling, through 
over-activation of JNK (9). As excessive FFAs 
have been shown to trigger ER stress in 
pancreatic β-cells (20), we examined whether 
palmitate caused ER stress in H4IIEC3 
hepatocytes. ER stress induces the spliced form 
of XBP-1 (XBP-1s), which up-regulates the 
transcription of molecular chaperones, including 
the 78-kD glucose-regulated/binding 
immunoglobulin protein (GRP78) (21). 
Palmitate at 0.25 mM did not alter the expression 
level of GRP78 mRNA or the splicing pattern of 
XBP-1, unlike tunicamycin, an agent commonly 
used to induce ER stress (Supplemental Fig. 3). 
Next, we compared the impact of palmitate and 
tunicamycin on insulin-stimulated signal 
transduction and JNK activation (Supplemental 
Fig. 4). The inhibitory effect of tunicamycin on 
insulin-stimulated serine phosphorylation of Akt 
was mild and not significant, compared with that 
of palmitate. Additionally, the increment in 
phosphorylated JNK by tunicamycin was lower 
and not significant compared with that of 
palmitate. These results suggest that ER stress 
played a minor role in palmitate-induced JNK 
activation and cellular insulin resistance in 
H4IIEC3 hepatocytes. 
Palmitate Induced Reactive Oxygen Species 
(ROS) Production—In addition to ER stress, 
increased cellular ROS levels are known to 
stimulate threonine phosphorylation of JNK (22). 
Indeed, ROS levels are increased in clinical 
conditions associated with insulin resistance, 
such as sepsis, burn injuries, obesity, and type 2 
diabetes (23). Furthermore, FFAs have been 
reported to generate ROS in various cells such as 
pancreatic islet cells (24), cardiac myocytes (25), 
and adipocytes (23). 
Thus, we hypothesized that palmitate 
increased intracellular ROS production and 
thereby activated JNK, leading to the impaired 
insulin signaling. To evaluate this, H4IIEC3 
hepatocytes were incubated with H2DCFDA, a 
fluorescent probe, to visualize intracellular ROS, 
with or without palmitate. H2DCFDA-associated 
fluorescence was elevated by 58% after 
incubation with 0.25 mM palmitate for 8 h, and 
palmitate induced more ROS production than 
oleate (Fig. 4). Consistent with this, the amount 
of protein carbonyls, a marker of oxidative stress, 
significantly increased in palmitate-treated 
hepatocytes (4.6 ± 0.5 nmol/mg protein), 
compared with control cells (3.1 ± 0.4 nmol/mg 
protein). These results suggest that FFAs, 
especially palmitate, can cause ROS production 
and oxidative stress in H4IIEC3 hepatocytes. 
Anti-oxidants Prevented Palmitate-Induced 
Insulin Resistance—We next sought to test 
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whether palmitate-induced ROS overproduction 
had a causal role in insulin resistance by 
assessing whether two anti-oxidant reagents, 
N-acetyl-L-cysteine (NAC) and α-tocopherol, 
could also act as insulin sensitizers. NAC and 
α-tocopherol dose-dependently suppressed 
palmitate-induced intracellular ROS production; 
NAC at 10 mM and α-tocopherol at 0.4 mM 
suppressed ROS production by 50% and 60%, 
respectively (Fig. 5). In parallel with decreased 
ROS levels, the anti-oxidants recovered the 
insulin-stimulated Akt phosphorylation impaired 
by palmitate; NAC at 10 mM and α-tocopherol at 
0.4 mM recovered the phosphorylation by 40% 
and 35%, respectively (Fig. 6). Furthermore, 
these anti-oxidants suppressed palmitate-induced 
JNK phosphorylation; NAC at 10 mM and 
α-tocopherol at 0.4 mM suppressed it by 80% 
and 55%, respectively (Fig. 7). These results 
suggest that palmitate increased ROS levels in 
H4IIEC3 hepatocytes and thereby activated JNK, 
resulting in insulin resistance. 
Palmitate Induced ROS Overproduction in 
Mitochondria—To define the source of ROS 
induced by palmitate in H4IIEC3 hepatocytes, 
we examined the cellular pathway involved in 
ROS production, including NADPH oxidase, 
xanthine oxidase, and mitochondria-mediated 
pathways. Palmitate-induced ROS production 
was markedly suppressed by rotenone, an 
inhibitor of mitochondrial respiratory chain 
complex I; thenoyltrifluoroacetone (TTFA), an 
inhibitor of mitochondrial respiratory chain 
complex II; and carbonyl cyanide 
m-chlorophenylhydrazone (CCCP), an uncoupler 
of oxidative phosphorylation (Fig. 8). In contrast, 
ROS production in palmitate-treated H4IIEC3 
cells was not suppressed by apocynin, an 
inhibitor of NADPH oxidase, or oxypurinol, an 
inhibitor of xanthine oxidase. These results 
suggest that the mitochondrial respiratory chain 
is involved in palmitate-induced ROS 
overproduction in H4IIEC3 hepatocytes. 
Palmitate Increased ROS through the 
Mitochondrial Fatty Acid 
β-oxidation-Respiratory Chain—FFAs are 
metabolized in the mitochondrial fatty acid 
β-oxidation pathway, which supplies the 
mitochondrial respiratory chain with electrons. 
Large amounts of electrons entering the 
respiratory chain may cause abnormal reduction 
of oxygen, leading to ROS production. Thus, we 
next examined whether palmitate-induced ROS 
production was dependent on mitochondrial fatty 
acid β-oxidation. Carnitine 
palmitoyltransferase-1a (CPT-1a) is the 
rate-limiting enzyme in mitochondrial fatty acid 
β-oxidation. As expected, etomoxir, a CPT-1 
inhibitor, decreased palmitate-induced ROS 
production, by 80% (Fig. 9A). Furthermore, 
palmitate, but not oleate, significantly increased 
expression of the CPT-1a gene (Fig. 9B). This 
up-regulation may contribute to 
palmitate-induced ROS overproduction, because 
the accelerated β-oxidation should cause 
excessive electron flux in the respiratory chain. 
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DISCUSSION 
In the present study, we investigated the 
direct action of fatty acids on insulin signaling in 
hepatocytes. The saturated fatty acid palmitate, 
but not the unsaturated fatty acid oleate, impaired 
insulin-induced tyrosine phosphorylation of 
IRS-2, serine phosphorylation of Akt, and serine 
phosphorylation of GSK-3α, all of which are 
indicative of insulin resistance in cultured 
H4IIEC3 hepatocytes. Unlike in vivo findings (6), 
the expression of the SREBP-1c gene was 
down-regulated by adding palmitate to cultured 
H4IIEC3 hepatocytes, which is likely a result of 
a negative feedback loop for fatty acid synthesis, 
and IRS-2 protein levels were unaffected. 
FFA-induced insulin resistance has been reported 
in other insulin-sensitive cells such as adipocytes 
(18) and skeletal muscle cells (26). These studies, 
together with the present results, suggest that 
FFA inhibits insulin signaling at the level of 
tyrosine phosphorylation of IRSs, regardless of 
cell type. Similar to the findings in 3T3-L1 
adipocytes (18) and primary mouse hepatocytes 
and pancreatic β-cells (16), the activation of JNK, 
a known suppressor of the tyrosine 
phosphorylation of IRSs, was involved in 
FFA-induced tyrosine phosphorylation of IRS-2 
in cultured H4IIEC3 hepatocytes. Because a JNK 
inhibitor, SP600125, largely restored 
palmitate-induced impairment of the insulin 
signaling pathway, JNK activation seems to play 
a major role in the development of 
palmitate-induced insulin resistance in H4IIEC3 
hepatocytes. Our results support in vivo finding 
that JNK is activated in the liver of an animal 
model of obesity and diabetes in which FFA 
influx into the liver is elevated (9,27). The 
overexpression of JNK in mouse liver resulted in 
hepatic insulin resistance at the level of IRS 
tyrosine phosphorylation, and the overexpression 
of a dominant negative mutant of JNK in the liver 
accelerated hepatic insulin signaling (17). 
Given that JNK is activated by many types 
of cellular stresses (28), we next searched for a 
link between palmitate treatment and JNK 
activation in H4IIEC3 hepatocytes. ER stress 
was unlikely to mediate palmitate-induced 
insulin resistance in H4IIEC3 hepatocytes, 
because palmitate caused insulin resistance 
independent of ER stress, whereas tunicamycin 
caused ER stress without affecting insulin action. 
Instead, we found that palmitate-induced ROS 
generation mediated insulin resistance. ROS are 
one of many factors suggested to have a possible 
role in insulin resistance (29,30). ROS include 
reactive products such as superoxide anion, 
hydrogen peroxide, and hydroxyl radical, which 
are formed as by-products of mitochondrial 
oxidative phosphorylation (OXPHOS). Thus, as 
a rule, increased mitochondrial OXPHOS flux 
leads to increased formation of ROS (31,32). 
ROS can also be produced during β-oxidation of 
fatty acids, especially as a by-product of 
peroxisomal acyl-CoA oxidase activity (32). 
Additionally, ROS can be produced by dedicated 
enzymes such as NADPH oxidase (33) present in 
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phagocytic cells, where ROS are an important 
part of cellular defense mechanisms. Using 
specific inhibitors of subcellular ROS, we 
identified mitochondrial OXPHOS as an 
important source of palmitate-induced ROS 
generation in H4IIEC3 hepatocytes. FFAs supply 
mitochondrial OXPHOS with electrons through 
mitochondrial fatty acid β-oxidation. A final 
metabolite of fatty acids, acetyl-CoA, is 
metabolized in the TCA cycle. In the processes of 
fatty acid β-oxidation and the TCA cycle, NADH 
and FADH2 are generated and could supply 
excessive electrons for OXPHOS. 
NAC, a scavenger of ROS, 
dose-dependently restored glutathione in 
palmitate-treated cells (Supplemental Fig. 5). 
However, glutathione restoration by NAC was 
unable to completely rescue palmitate-induced 
insulin resistance. Furthermore, the combination 
of NAC and alpha-tocopherol did not completely 
reverse JNK activation (Supplemental Fig. 6A 
and 6B) and only partly rescued 
palmitate-induced insulin resistance 
(Supplemental Fig. 7A and 7B). Therefore, other 
mechanisms may also be involved in insulin 
resistance caused by palmitate.  
De novo ceramide synthesis is a potential 
pathway contributing to palmitate-induced JNK 
activation. Ceramide derived from saturated fatty 
acids has been reported to activate JNK and 
inhibit insulin-induced Akt phosphorylation in 
myocytes (34–36). In our investigation, palmitate 
increased the intracellular content of ceramide in 
H4IIEC3 hepatocytes (Supplemental Fig 8). 
Unfortunately, even at the maximum myriosin 
concentration, the intracellular accumulation of 
ceramide was not blocked by myriosin, a potent 
inhibitor of serine palmitoyltransferase at the 
first step in ceramide biosynthesis, 
(Supplemental Fig. 8). Furthermore, ceramide 
accumulation was not blocked when myriosin 
was used in combination with fumonisin B1, an 
inhibitor of ceramide synthase (data not shown). 
Therefore, we cannot rule out the possibility that 
intracellular ceramide contributes to 
palmitate-induced insulin resistance in H4IIEC3 
hepatocytes. Further studies are required to 
assess the role of the ceramide pathway in 
palmitate-induced insulin resistance in 
hepatocytes.  
In the present study, etomoxir, an inhibitor 
of CPT-1, decreased palmitate-induced 
intracellular ROS production. Additionally, 
palmitate, but not oleate, significantly increased 
the expression of the CPT-1a gene, which may 
account for the observed differences in insulin 
action between palmitate and oleate.  
Recently, it was reported that fatty acid 
composition may be a determinant in insulin 
sensitivity (37,38). In this regard, we investigated 
the effect of oleate on insulin signaling in 
palmitate-treated hepatocytes. Surprisingly, 
oleate dose-dependently reversed 
palmitate-induced ROS generation, JNK 
phosphorylation, and rescued palmitate-induced 
phosphorylation of Akt (Takayama and 
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Takamura, unpublished data). Further 
investigations aimed at elucidating the molecular 
basis underlying the differential roles and 
interactions of FFAs are required.  
In conclusion, this study identified 
mitochondrial ROS generation as a critical factor 
in palmitate-induced hepatic insulin resistance. 
Palmitate may induce CPT-1 expression, 
accelerate metabolism, supply excess electrons 
for mitochondrial OXPHOS, and generate ROS. 
ROS then desensitize the insulin signaling 
pathway by activating JNK, impairing tyrosine 
phosphorylation of IRS-2, and causing hepatic 
insulin resistance. The results suggest that an 
initial event in high-fat/sucrose diet-induced or 
obesity-induced insulin resistance in the liver is 
mitochondrial ROS generation, which could 
potentially be a therapeutic target. In addition to 
previously suggested JNK inhibitors or 
anti-oxidants, mitochondrial uncouplers such as 
CCCP may provide a candidate therapeutic 
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FIGURE 1. Effects of palmitate and oleate on insulin-stimulated tyrosine phosphorylation of 
IRS-2 and serine phosphorylation of Akt and GSK-3 in H4IIEC3 hepatocytes. (A) H4IIEC3 cells 
were incubated in the presence or absence of palmitate (Pal) or oleate (Ole) for 16 h prior to 
stimulation with insulin (1 ng/mL, 15 min). Total cell lysates were resolved by SDS-PAGE, 
transferred to a PVDF membrane, and immunoblotted with the indicated antibodies. Total cell 
lysates were subjected to immunoprecipitation with phosphotyrosine antibody prior to 
SDS-PAGE to examine tyrosine phosphorylation of IRS-2. Detection was by enhanced 
chemiluminescence. Representative blots are shown. (B) The values from densitometry of three 
(p-IRS-2), eight (p-Akt), or five (p-GSK-3α) independent experiments were normalized to the 
level of total IRS-2, Akt, or GSK-3α protein, respectively, and expressed as the mean fold 
increase over control ± S.E. * p < 0.05, versus insulin treatment alone. ** p < 0.01, versus insulin 
treatment alone. 
 
FIGURE 2. Effects of palmitate and oleate on JNK activation in H4IIEC3 hepatocytes. 
(A) H4IIEC3 cells were incubated in the presence or absence of FFAs [palmitate (Pal) or oleate 
(Ole)] and the JNK inhibitor SP600125 (SP) for 16 h. Total cell lysates were resolved by 
SDS-PAGE, transferred to a PVDF membrane, and immunoblotted with the indicated antibodies. 
Detection was by enhanced chemiluminescence. Representative blots are shown. (B) The values 
from densitometry of four (p-JNK) independent experiments were normalized to the level of total 
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JNK (p-c-Jun was not normalized; n = 4) and expressed as the mean fold increase over control ± 
S.E. ** p < 0.01, versus control. †† p < 0.01, versus palmitate treatment. 
 
FIGURE 3. Effect of a JNK inhibitor on palmitate-induced alterations in insulin-stimulated 
phosphorylation of Akt and GSK-3 in H4IIEC3 hepatocytes. (A) H4IIEC3 cells were incubated in 
the presence or absence of palmitate (Pal) and the JNK inhibitor SP600125 (SP) for 16 h prior to 
stimulation with insulin (1 ng/mL, 15 min). Total cell lysates were resolved by SDS-PAGE, 
transferred to a PVDF membrane, and immunoblotted with the indicated antibodies. Detection 
was by enhanced chemiluminescence. Representative blots are shown. (B) The values from 
densitometry of four (p-Akt or p-GSK-3) independent experiments were normalized to the level 
of total Akt or GSK-3 protein, respectively, and expressed as the mean fold increase over control 
± S.E. ** p < 0.01, versus palmitate treatment. 
 
FIGURE 4. Effect of palmitate on oxidative stress in H4IIEC3 hepatocytes. H4IIEC3 cells were 
incubated in the presence or absence of palmitate (Pal) or oleate (Ole) for 8 h. Intracellular ROS 
production was quantified using the fluorescent probe H2DCFDA. The values are expressed as 
mean fold increase over control ± S.E. (n = 4). ** p < 0.01, versus control. †† p < 0.01, versus 
0.25 mM palmitate treatment. 
 
FIGURE 5. Effects of anti-oxidants on palmitate-induced intracellular ROS production in 
H4IIEC3 hepatocytes. H4IIEC3 cells were incubated in the presence or absence of palmitate (Pal) 
and anti-oxidants for 8 h. Intracellular ROS production was quantified using the fluorescent probe 
H2DCFDA. The values are expressed as mean fold increase over control ± S.E. (n = 4). * p < 0.05, 
versus palmitate treatment alone. ** p < 0.01, versus palmitate treatment alone. NAC, 
N-acetyl-L-cysteine; Toc, α-tocopherol. 
 
FIGURE 6. Effects of anti-oxidants on palmitate-induced alterations in insulin-stimulated serine 
phosphorylation of Akt in H4IIEC3 hepatocytes. (A) H4IIEC3 cells were incubated in the 
presence or absence of palmitate (Pal) and anti-oxidants for 16 h prior to stimulation with insulin 
(1ng/mL, 15 min). Total cell lysates were resolved by SDS-PAGE, transferred to a PVDF 
membrane, and immunoblotted with the indicated antibodies. Detection was by enhanced 
chemiluminescence. Representative blots are shown. (B) The values from densitometry of four 
(NAC) or five (α-tocopherol) independent experiments were normalized to the level of total Akt 
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protein and expressed as the mean fold increase over control ± S.E. * p < 0.05, versus palmitate 
treatment. NAC, N-acetyl-L-cysteine; Toc, α-tocopherol. 
 
FIGURE 7. Effects of anti-oxidants on palmitate-induced JNK activation in H4IIEC3 hepatocytes. 
(A) H4IIEC3 cells were incubated in the presence or absence of palmitate (Pal) and anti-oxidants 
for 16 h. Total cell lysates were resolved by SDS-PAGE, transferred to a PVDF membrane, and 
immunoblotted with the indicated antibodies. Detection was by enhanced chemiluminescence. 
Representative blots are shown. (B) The values from densitometry of four (NAC or α-tocopherol) 
independent experiments were normalized to the level of total JNK protein and expressed as the 
mean fold increase over control ± S.E. ** p < 0.01, versus palmitate treatment alone. NAC, 
N-acetyl-L-cysteine; Toc, α-tocopherol 
 
FIGURE 8. Effects of ROS-producing pathway inhibitors on palmitate-induced ROS production 
in H4IIEC3 hepatocytes. H4IIEC3 cells were incubated in the presence or absence of palmitate 
(Pal) and each ROS-producing pathway inhibitor for 8 h. Intracellular ROS production was 
quantified using the fluorescent probe H2DCFDA. The values are expressed as mean fold increase 
over control ± S.E. (n = 4). * p < 0.05, versus palmitate treatment alone. ** p < 0.01, versus 
palmitate treatment alone. Rot, rotenone; Apo, apocynin; Oxy, oxypurinol 
 
FIGURE 9. Involvement of mitochondrial fatty acid oxidation in palmitate-induced ROS 
production. (A) H4IIEC3 cells were incubated in the presence or absence of palmitate (Pal) and 
the CPT-1 inhibitor etomoxir (Eto) for 8 h. Intracellular ROS production was quantified using the 
fluorescent probe H2DCFDA. The values are expressed as mean fold increase over control ± S.E. 
(n = 4). (B) H4IIEC3 cells were incubated in the presence or absence of palmitate (Pal) or oleate 
(Ole) for 16 h. Total RNA was extracted and subjected to reverse transcription. Using the cDNA 
as a template, the amounts of CPT-1 mRNA were detected by real-time PCR. The values were 
normalized to the level of 18S ribosomal RNA and expressed as mean fold increase over 
control ± S.E. (n = 3). * p < 0.05, versus control. ** p < 0.01, versus palmitate treatment alone. 
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Supplemental Fig. 1. Effects of palmitate and oleate on insulin-stimulated serine phosphorylation 
of Akt in HepG2 cells. HepG2 cells were incubated in the presence or absence of FFAs A, 
palmitate (Pal); B, oleate (Ole)] for 16 h prior to stimulation with insulin (1 ng/mL, 15 min). Total 
cell lysates were resolved by SDS-PAGE, transferred to a PVDF membrane, and immunoblotted 
with the indicated antibodies. Detection was by enhanced chemiluminescence. Representative 


















 Supplemental Fig. 2. Effects of palmitate and oleate on expression levels of the SREBP-1c and 
IRS-2 genes in H4IIEC3 hepatocytes. H4IIEC3 cells were incubated in the presence or absence of 
palmitate (Pal) or oleate (Ole) for 16 h. Total RNA was extracted and subjected to reverse 
transcription. Using the cDNA as a template, the amounts of SREBP-1c and IRS-2 mRNA were 
detected by real-time PCR. The values are normalized to the level of 18S ribosomal RNA and 
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Supplemental Fig. 3. Effect of palmitate on ER stress in H4IIEC3 hepatocytes. H4IIEC3 cells 
were incubated in the presence or absence of palmitate (Pal) or the ER stress inducer tunicamycin 
(Tun) for 16 h. Total RNA was extracted and subjected to reverse transcription. Using the cDNA 
as a template, the amounts of GRP78 mRNA (A) or XBP-1 mRNA splicing (B) were detected by 
real-time PCR or reverse transcription PCR, respectively. (A) The values were normalized to the 
level of 18S ribosomal RNA and expressed as mean fold increase over control ± S.E. (n = 3). 























































Supplemental Fig. 4. Comparison of insulin signaling with palmitate treatment and with the ER 
stress inducer tunicamycin in H4IIEC3 hepatocytes. (A) H4IIEC3 cells were incubated in the 
presence or absence of palmitate (Pal) or the ER stress inducer tunicamycin (Tun) for 16 h prior to 
stimulation with insulin (1 ng/mL, 15 min). Total cell lysates were resolved by SDS-PAGE, 
transferred to a PVDF membrane, and immunoblotted with the indicated antibodies. Detection 
was by enhanced chemiluminescence. Representative blots are shown. (B) The values from 
densitometry of four (p-Akt) or three (p-JNK) independent experiments are normalized to the 
level of total Akt or JNK protein, respectively, and expressed as the mean fold increase over 
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Supplemental Fig. 5. Restoration of intracellular GSH levels by N-acetyl-cysteine (NAC) in 
palmitate-treated H4IIEC hepatocytes. H4IIEC cells were incubated in the absence or presence of 
palmitate (Pal) and NAC for 16 h. Intracellular GSH levels were determined using a commercial 
kit (Total Glutathione Quantification Kit, DOJINDO). The values from three independent 
experiments were normalized to the level of total protein, respectively, and expressed as means ± 
S.E. (n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001 versus control. † P < 0.05, †† P < 0.01 versus 
0.25 mM Pal. 
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Supplemental Fig. 6. N-acetyl-cysteine (NAC) and α-tocopherol (α-Toc) decrease 
palmitate-induced JNK activation in H4IIEC hepatocytes. (A) H4IIEC cells were incubated in the 
absence or presence of palmitate (Pal) and NAC and α-Toc for 16 prior to stimulation with insulin 
(1 ng/mL, 15 min). Total cell lysates were resolved by SDS-PAGE, transferred to a PVDF 
membrane, and immunoblotted with the indicated antibodies. Representative blots are shown. 
(B) The densitometric values from three independent p-JNK experiments were normalized to the 
level of total JNK and expressed as the mean fold increase over control ± S.E. * P < 0.05, 
** P < 0.01 versus 0.25 mM Pal treatment. † P < 0.05 versus 0.25 mM Pal/0.1 mM NAC 
treatment. 
 34 
Supplemental Fig. 7. N-acetyl-cysteine (NAC) and α-tocopherol (α-Toc) reverse 
palmitate-induced changes in insulin-stimulated Akt phosphorylation in H4IIEC hepatocytes. 
(A) H4IIEC cells were incubated in the absence or presence of palmitate (Pal) and NAC and 
α-Toc for 16 h prior to stimulation with insulin (1 ng/mL, 15 min). Proteins in total cell lysates 
were resolved by SDS-PAGE, transferred to a PVDF membrane, and immunoblotted with the 
indicated antibodies. Representative blots are shown. (B) The densitometric values from three 
independent p-Akt experiments were normalized to total Akt protein and expressed as the mean 
fold increase over control ± S.E. * P < 0.05 , ** P < 0.01, *** P < 0.001 versus 0.25 mM Pal 
treatment. 
 35 
Supplemental Fig. 8. Effect of myriocin (Myr) on ceramide synthesis in H4IIEC hepatocytes. 
(A) H4IIEC cells were incubated in the absence or presence of palmitate (Pal) and Myr for 16 h. 
Ceramide was measured according to an established method (Araki et al., PNAS 94:11946, 1997). 
Signals were detected using a Typhoon 9400 Imager (GE Healthcare Bio-Sciences). 
Representative blots are shown. (B) The densitometric values from three independent 
experiments were normalized to the level of total protein and expressed as the mean fold increase 
over control ± S.E. * P < 0.05, *** P < 0.001 versus control. † P < 0.05 versus 0.25 mM Pal. 
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